Free paper

Treating age-related changes in somatotrophic hormones, sleep, and cognition

Michael V. Vitiello, PhD; Robert S. Schwartz, MD; Karen E. Moe, PhD;
Giuliana Mazzoni, PhD; George R. Merriam, MD

Many of the body's systems that function to maintain optimal health and well-being decline with advancing age. Aerobic capacity, muscle mass, and strength all progressively decline. Significant sleep disturbances are associated with increases in morbidity and mortality. Cognition declines, impacting an older individual's ability to function independently. Interventions that could at least stabilize or possibly improve functional capacity, sleep quality, and cognitive function have the theoretical potential to prolong an older individual's ability to live independently, and interest in their possible utility is growing rapidly. One such intervention may be stimulation of the "somatotrophic" axis via growth hormone–releasing hormone (GHRH). Here we review the evidence for such somatotrophic interventions. We also report preliminary findings on the effects of chronic GHRH treatment on the somatotrophic hormones, body composition, functional status, sleep, and cognitive function of healthy older men and women from two major GHRH intervention studies, one recently completed and the other ongoing.

Many of the body's systems that function to maintain optimal health and well-being decline with advancing age. Aerobic capacity, muscle mass, and strength all progressively decline with age. This loss of muscle mass, or sarcopenia, and the accompanying reduction in strength increase the risk of falls and their complications, and for many individuals the associated loss of physical functional capacity leads to increasing difficulty in living independently. Complaints of poor sleep are common in older populations. Insomnia reduces quality of life and is often a factor in decisions to seek health care. Sleep complaints often lead to overmedication and sedation of the elderly, with the numerous potential attendant problems, including increased morbidity and mortality. Finally, cognition also declines with advancing age, particularly those cognitive functions that involve novel problem solving and psychomotor processing speed, with its own related impact on the older individual's ability to function independently.

Interventions that could at least stabilize or possibly improve functional capacity, sleep quality, and cognitive function theoretically have the potential to prolong an older individual's ability to live independently, and interest in their possible utility is growing rapidly. There is increasing evidence that the functioning of many of these systems may be improved through stimulation of the "somatotrophic" or growth hormone (GH)–insulinlike growth factor–I (IGF-I) axis. Levels of GH and IGF-I rise rapidly at puberty, remain high during early adulthood, and then decline progressively with aging. It has been suggested that with age there is a "somatopause" of GH-

Address for correspondence: Michael V. Vitiello, PhD, Psychiatry and Behavioral Sciences, Box 356560, University of Washington, Seattle, WA 98195-6560, USA (e-mail: vitiello@u.washington.edu)

Author affiliations: Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Wash (Michael V. Vitiello, Karen E. Moe); Department of Medicine, University of Washington, Seattle, Wash (George R. Merriam); Veterans Affairs Puget Sound Health Care System, Seattle, Wash (George R. Merriam); Department of Medicine, University of Colorado, Denver, Co (Robert S. Schwartz); Department of Psychology, Seton Hall University, South Orange, NJ, USA (Giuliana Mazzoni)

Free paper

IGF-I anabolic status in both sexes, which is reversible by GH restoration or stimulation therapies. Because the aging pituitary remains capable of synthesizing and secreting increased amounts of GH if appropriately stimulated, several recent studies have examined the effects of administering GH secretagogues (GHSs)—factors that stimulate GH secretion—as an alternative to GH treatment. These secretagogues include analogs of the endogenous hypothalamic GHS, growth hormone–releasing hormone (GHRH).

Here we briefly review the evidence for such somatotrophic interventions. We also report preliminary findings on the effects of chronic GHRH treatment on the somatotrophic hormones, body composition, functional status, sleep, and cognitive function of healthy older men and women from two major GHRH intervention studies, one recently completed and the other ongoing.

Aging, somatotrophic hormones, and body composition

GH is secreted by the pituitary under the hypothalamic control of at least three peptide systems: somatostatin (somatotropin-release inhibiting factor [SRIF]), which inhibits GH secretion; GHRH; and a second recently characterized secretagogue, ghrelin.[1] The combined influences of these systems yield a pulsatile pattern of GH secretion in peripheral blood. GH exerts its effects by binding to its own receptor as well as by stimulating the synthesis of IGF-I. The liver is the primary contributor to levels of IGF-I in the systemic circulation, but IGF-I is generated in many GH target tissues, and local effects may be more important than those of circulating IGF-I of hepatic origin.[1]

With aging, there are declines in the GH-IGF-I axis[2] and in lean body mass.[3] The amplitude of stimulated GH release as well as integrated 24-hour GH levels have been observed to decline with age.[4-8] Parallel declines in IGF-I have also been observed by ourselves and others.[4,9,10] A variety of mechanisms could potentially underlie this decline in GH secretion with aging. Current evidence suggests that this is most likely the result of both a decrease in GHS activity and an increase in somatostatin, but not an intrinsic loss of pituitary capacity to secrete GH. Consequently, stimulation of the somatotrophic axis with GHRH is a potential alternative to replacement with GH itself in normal aging. GHSs such as GHRH may result in a more "physiological" stimulus to GH secretion than GH per se. GHRH yields a pulsatile GH secretion as opposed the continuously elevated levels seen with GH administration. Further, when a secretagogue is used, the normal negative feedback regulation by IGF-I on pituitary GH secretion is preserved, offering the possibility of reduced side effects.

The hypothesis that age-related decreases in IGF-I and protein synthesis are due to an age-associated decrement in GH secretion is supported by studies showing that exogenous GH administration restores plasma IGF-I to youthful levels in aged animals and humans.[11-13] Similarly, IGF-I restores protein synthesis and lean body mass (LBM) in animals and humans.[11,14,15] Thus, the age changes in the GH-IGF-I axis and LBM appear to be at least partly reversible.

Aging, sleep, and somatotrophic hormones

Nearly 40% of the older (over 55 years) population suffers from and complains of insomnia, fragmented sleep, and poor sleep quality, more than any other age group.[16-19] Older individuals are twice as likely to complain of difficulties falling asleep and remaining asleep, and of having less restful sleep than younger individuals. These complaints of poor sleep are supported by objective findings in the sleep laboratory, which include: (i) a decrease in stages 3 and 4 sleep (slow-wave sleep [SWS]), often called "deep" sleep, and the delta electroencephalography (EEG) activity that characterizes it; (ii) an increase in the number of awakenings from sleep and an increase in the total time spent awake; and (iii) a decrease in the rapid-eye-movement (REM) sleep stage. We[20,21] and others have shown that these disturbed sleep patterns are seen even in optimally healthy, noncomplaining, elderly individuals who have been carefully screened for possible medical and psychological factors that might disrupt sleep.

The public health burden associated with sleep distur-
bances in the elderly is considerable. These sleep distur-
bances have been linked to increased use of sedative
hypnotics,[22-25] greater use of the health services,[22,26-28] and
reduced functional ability and quality of life.[17,18,29,30] Fur-
ther, these sleep disturbances are frequently comorbid
with physical and mental illness,[22,28,31-34] are often a major
reason for nursing home placement,[35,36] and may predict
future declines in physical health and mortality.[35,37-42] The
consistent report of disturbed sleep[16,43] by the elderly
may account for the disproportionate prescription of
sedative hypnotics to the elderly population.[16,19] Hyp-
notic medication offers only short-term efficacy and, in
the long term, may itself disrupt sleep.[44,45] Hypnotic use
may also lead to exacerbation of sleep apnea and day-
time carryover effects, such as sedation, delirium, falls,
fractures, cognitive impairment, and anterograde amne-
sia[46] and has been associated with increased morbidity
and mortality.[35,37-42] The 1991 National Institutes of
Health (NIH) Consensus Conference on the Treatment
of Sleep Disorders of Older People concluded that
"nonsedative hypnotic approaches to improve sleep
quality in the elderly population are sorely needed."[19]
Pulsatile GH secretion continues with aging, but with a
pattern of diminished GH pulse amplitude.[4] In particu-
lar, nighttime GH secretion declines, so that there is
often no longer a clear night–day GH rhythm. SWS also
declines with aging, although it is unclear whether the
GH decline is due to the reduction in SWS, whether
SWS deteriorates because of the decline in GH, or
whether both are decreased because of a common
reduction at a higher level of regulation (eg, GHRH).
Recent studies have shown that sleep is influenced by
clinical extremes of GH status[47,48] and that sleep can be
improved in response to acute GH administration[49] or
stimulation of the GH-IGF-I axis using GHRH.[50] Acute
GHRH administration increases SWS[51] and acute
decreases in GH status by a GH-releasing factor antag-
onist decrease slow-wave amplitude and SWS duration[52]
in animals. Among hormones, GHRH displays the best-
documented sleep-promoting activity and is clearly
implicated in the regulation of sleep, specifically non-
REM sleep. GHRH hypothalamic neurons projecting to
the basal forebrain, specifically the medial preoptic area,
likely act directly to increase non-REM/SWS.[53] Three
independent laboratories have recently reported that
GHRH promotes sleep in healthy young subjects,[54-58]
although two older studies reported no such effect[59,60]

and there is some evidence to suggest that the impact of
GHRH on the sleep of the elderly may be weaker.[61,62]

Aging, cognition, and somatotrophic hormones

While it has been extensively documented that significant
changes in several major areas of cognitive function devel-
op with advancing age, such declines do not develop uni-
formly. For example, some components of memory remain
relatively intact with advancing age (eg, primary or short-
term memory), while others do not (eg, secondary or long-
term memory). A major distinction that is useful for
describing those functions that are preserved versus
impaired by advancing age was proposed by Cattell, ie, the
concepts of crystallized versus fluid intelligence.[63] Crystal-
lized intelligence, or abilities dependent upon accumulat-
ed experience and education, such as general knowledge,
culture-specific rules, and formal verbal reasoning, are rel-
atively resistant to age-related decline. Conversely, fluid
intelligence, or abilities involving concept formation, rule
discovery, planning behavior, and nonverbal reasoning,
markedly decline with advancing age. Recently, Salthouse
and others have suggested that this age-related change in
fluid intelligence is at least partially the result of decreas-
es in mental processing speed.[64,65]
It has been suggested that the declines in GH and IGF-I
observed with advancing age may contribute to the
impaired cognitive function associated with aging and
perhaps to that seen in neurodegenerative diseases such
as Alzheimer's disease.[66-70] GH and IGF-I are present in
the cerebrospinal fluid and both have binding sites in the
central nervous system (CNS), particularly in the hip-
pocampus, a brain structure crucial to learning and mem-
ory.[71-73] Significant negative correlations have been
observed between advancing age and the density of GH
binding sites, particularly in the pituitary, hypothalamus,
and hippocampus.[74,75] We and others have reported posi-
tive correlations between IGF-I and cognition in the
healthy elderly.[76,77] Further, impairments in cognitive
function have been reported in adults with either child-
hood- or adult-onset GH deficiency.[78,79] Finally, two
recent, placebo-controlled trials[80,81] of 6 to 24 months of
GH treatment in GH-deficient adults reported improved
cognitive function with GH replacement. However, it
should be noted that a third, similar, placebo-controlled
study[82] observed no such improvement after 18 months
of GH treatment.

Free paper

Chronic GHRH treatment: preliminary results

Taken as a whole, the literature reviewed above suggests that augmenting the somatotrophic axis with chronic GHRH may have an impact not only on GH, IGF-I, body composition, and therefore physical function status, but also on CNS function, specifically sleep quality and cognitive function. At the University of Washington, we have been conducting two NIH-supported studies of the effects of chronic GHRH administration on hormonal and functional end points in healthy older women and men. One recently completed study (grant number RO1-AG10943 to R. S. Schwartz) assessed the combined effects of 6 months' treatment with GHRH or placebo and an exercise intervention on body composition, strength, and functional status in healthy older women not taking estrogen replacement therapy. The second, ongoing study (grant number RO1-MH53575 to M. V. Vitiello) examined the effects of 5 months' treatment with GHRH or placebo on GH profiles, body composition, and functional status including sleep, cognition, and physical function in healthy older men and women; this trial is still in progress. Both studies involved the same drug treatment: a single evening subcutaneous injection of GHRH (14 µg/kg [≈1 mg] of GHRH(1-29)NH$_2$, sermorelin acetate, Geref®, Serono Laboratories Inc). Because both of these studies involve women on estrogen replacement therapy (ERT) and women not on estrogen replacement therapy (NERT) as well as men, it will ultimately be possible to examine not only gender but also estrogen replacement status effects on the impact of GHRH treatment. While one of these studies is still ongoing and only preliminary results from both studies have been reported to date, a few early, tentative conclusions can be offered.

Somatotrophic hormones, body composition, and physical function

These studies show that once-nightly doses of GHRH are well tolerated and can significantly enhance GH secretion and elevate IGF-I levels. They also demonstrate differences in responses among gender/estrogen replacement groups, and limitations in current GHRH formulations. The side effects typically reported in GH treatment studies, mainly peripheral edema and arthralgias, were very uncommon. Rarely, GHRH-treated patients reported erythema or swelling at the injection site. Male subjects doubled their 24-h GH secretion and experienced a 40% rise in IGF-I levels.[83] NERT women had a similar response, with an average 30% increase in IGF-I levels over baseline. ERT women had the most vigorous increase in GH in response to GHRH, but, despite this, they experienced the lowest IGF-I increments, averaging <10%. These results suggest that oral estrogen replacement induces relative GH resistance. This last result is comparable to that reported in estrogenized vs nonestrogenized adult patients with GH deficiency receiving GH replacement.[84] While the significant increase in GH was maintained for the duration of the treatment period, there are clear limitations with the current GHRH formulation. A single, large burst of GH secretion was observed immediately following each evening injection. Nighttime pulsatile GH secretion was not restored. Further, late-night GH secretion was reduced compared with baseline GH profiles. This could represent a temporary exhaustion of releasable GH stores following the acute supraphysiological effect, or negative feedback suppression by the increased circulating levels of IGF-I. Daytime GH secretion, while still low, was not suppressed, favoring the former explanation. The net effect of GHRH treatment is the observed near-doubling of overall GH secretion and a ≈40% increase in IGF-I.

Body composition measured by whole-body dual energy x-ray absorptiometry (DEXA) scans shows a significant decrease (≈5%) in percentage body fat in men and NERT women, with a reciprocal increase in LBM.[83,85,86] As with the effect on IGF-I, the GHRH effect on body composition is blunted in ERT women; it appears that oral estrogen induces a resistance to GH action. This blockade is qualitatively similar to the effect seen in ERT GH-deficient women receiving GH treatment.[84]

In these studies, physical function was assessed by both standard measures of strength and a continuous-scale physical functional performance (PFP) test developed at the University of Washington.[87] The PFP is designed to assess the higher capabilities of subjects living independently and it has been shown to measure deterioration in physical function, which was not clinically apparent, over a 6-month period. PFP results for the current studies are very preliminary. The effects of GHRH appear to vary by specific task, some showing improvement in the actively treated group and no change in those receiving placebo, while others show no change with GHRH and deterioration with placebo.[85,88]

Sleep quality and cognitive function

Both objective and subjective sleep are being measured in the ongoing NIMH-funded study; however, preliminary data are currently available only for subjectively rated sleep quality. The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire, which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.[89] The sum of the scores for these seven components yields one global score with a maximum possible score of 25. A global PSQI score greater than 5 has been shown to significantly distinguish good and poor sleepers, although this criterion was not developed on older subjects where higher scores are to be expected. Counterintuitively, GHRH treatment was associated with a very small but significant increase in PSQI total score (4.1 ± 2.8 vs 5.4 ± 2.8, N=37, $P<0.05$) suggesting that chronic GHRH resulted in poorer sleep. No change in PSQI was noted for the placebo group (4.5 ± 2.9 vs 4.6 ± 2.7, N=38). Examination of the PSQI's seven component scores within the GHRH group revealed no clear impact of GHRH treatment on any of the components, suggesting that this may be a nonspecific finding. The real significance of this small increase in subjectively rated sleep quality remains unclear and awaits analysis of the full study sample and the corresponding analysis of objective sleep measures.

We and others have reported positive correlations between IGF-I and cognition in the healthy elderly.[76,77] In a previously published abstract of a study in 64 patients,[90] we reported that GHRH treatment resulted in significantly improved performance (5% to 7%) relative to placebo on several cognitive tasks, particularly those involving psychomotor and perceptual processing speed. The pattern of results observed in the larger group of 75 patients, which we reported at the 2000 Meeting of the Gerontological Association of America, supports this initial, tentative conclusion and further indicates that the beneficial impact of GHRH treatment may be observed in other cognitive tasks that are less dependent on processing speed. On the basis of the findings of this larger, but still incomplete sample, we conclude that 5 months of daily GHRH treatment may have a small, but significant, beneficial effect on the cog-

nitive abilities of healthy older men and women. These preliminary findings support the hypothesis that the age-related declines in the somatotrophic axis may be related to declines in cognition, and that supplementation of this neurohormonal deficit may partially ameliorate such cognitive deficits.

Summary of study on chronic GHRH treatment

Overall, it appears that once-daily GHRH injections can stimulate the desired increases in GH and IGF-I and result in significant increases in LBM and declines in fat mass, although these results are tempered by estrogen status in women. Alone, however, they do not support an indication for treatment unless these increases induce meaningful changes in muscle mass and functional capacity and other outcome measures. While GHRH treatment produced a single large burst of GH secretion immediately following each evening injection, a "youthful" nighttime pulsatile GH secretion pattern was not restored. This increase in overall GH and IGF-I levels may suffice for some effects mediated through GH and IGF-I (eg, changes in body composition and possibly improvements in cognitive function), but it is far from a restoration of nighttime pulsatile GH secretion, which may be required to support any possible beneficial effects on sleep quality. For this, a sustained-release formulation or an analog with a duration of action of at least 8 h will be needed. It must be emphasized that these conclusions regarding the effects of GHRH treatment are tentative, as more definitive results will not be available until both studies are completed and analyzed.

Conclusions

Our preliminary results show that once-daily evening subcutaneous injections of GHRH are well tolerated and can increase 24-h GH secretion, boost circulating levels of IGF-I, and improve body composition in older patients. Preliminary analyses also suggest beneficial effects on physical and cognitive performance. These findings, while encouraging further study, are far from the type of results that can support use of GHRH to "treat" aging.[1,91] As aging is not a disease, drug therapy cannot be encouraged until meaningful functional benefits are shown either in treatment or in the prevention of specific disorders associated with aging. The recent preliminary report of a multicenter European study

Free paper

showing that GH may accelerate recovery from hip fracture[92] is an example of such a finding. Nevertheless, the observed beneficial effects of GHRH and its minimal side effects are encouraging and indicate that future work in this area is well worth pursuing with the hope of ultimately improving the overall health and quality of life of the seniors, who currently represent the fastest-growing segment of our population. ❑

El tratamiento de los cambios relacionados con la edad a nivel de las hormonas somatotróficas, del sueño y de la cognición

Muchos de los sistemas del organismo que funcionan para mantener la salud y el bienestar en el óptimo declinan a medida que avanza la edad. La capacidad aeróbica, y la masa y la fuerza muscular declinan progresivamente. Las alteraciones significativas del sueño se asocian con aumentos en la morbilidad y en la mortalidad. La cognición declina, afectando la capacidad del individuo mayor para funcionar independientemente. Las intervenciones que puedan al menos estabilizar o posiblemente mejorar la capacidad funcional, la calidad del sueño y la función cognitiva tienen teóricamente el potencial de prolongar la capacidad de un individuo mayor para vivir independientemente, por lo que el interés en su posible utilidad está creciendo rápidamente. Una de tales intervenciones puede ser la estimulación del eje "somatotrófico" a través de la hormona liberadora de hormona del crecimiento (GHRH). Aquí nosotros revisamos la evidencia de tales intervenciones somatotróficas. Nosotros también damos cuenta, a partir de dos grandes estudios de intervención con GHRH (uno recientemente terminado y otro en curso), acerca de los hallazgos preliminares de los efectos del tratamiento crónico con GHRH sobre las hormonas somatotróficas, la composición del organismo, el estado funcional, el sueño, y la función cognitiva del hombre y la mujer mayores sanos.

Traitement des changements liés à l'âge au niveau des hormones somatotropes, du sommeil et de la cognition

La plupart des systèmes du corps humain dont la fonction est de maintenir un état optimal de bonne santé et de bien-être déclinent avec l'âge. La capacité aérobie, la masse et la force musculaires déclinent progressivement. Les troubles significatifs du sommeil sont associés à une augmentation de la mortalité et de la morbidité. Les capacités cognitives diminuent, retentissant sur l'autonomie des personnes âgées. Les interventions thérapeutiques susceptibles de stabiliser voire d'améliorer la capacité fonctionnelle, la qualité du sommeil et les fonctions cognitives ont en théorie le pouvoir de prolonger la capacité des sujets âgés de vivre de façon indépendante et suscitent de ce fait un intérêt croissant. La stimulation de l'axe somatotrope par l'intermédiaire de la somatocrinine (growth hormone–releasing hormone, GHRH) constitue l'une des modalités d'intervention possibles. Cet article fait le point sur les données concernant ce type de traitement. Nous rapportons également les résultats préliminaires de deux études, l'une en cours et l'autre récemment achevée, portant sur les effets du traitement chronique par GHRH sur les hormones somatotropes, la composition corporelle, l'état fonctionnel, le sommeil et la fonction cognitive d'hommes et de femmes âgés en bonne santé.

REFERENCES

1. Merriam GR, Kletke M, Barsness S, et al. Growth hormone-releasing hormone in normal aging: an update. *Todays Ther Trends.* 2000;18:335-354.
2. Kelijman M. Age-related alterations of the growth hormone/insulin-like-growth-factor I axis. *J Am Geriatr Soc.* 1991;39:295-307.
3. Fukagawa NK, Bandini LG, Young JB. Effect of age on body composition and resting metabolic rate. *Am J Physiol.* 1990;2159:E233-E238.
4. Ho KY, Evans WS, Blizzard RM. Effects of sex and age on the 24-hour profile of GH secretion in man: importance of endogenous estradiol concentrations. *J Clin Endocrinol Metab.* 1987;64:51-58.
5. Prinz P, Weitzman E, Cunningham G, Karacan I. Plasma growth hormone during sleep in young and aged men. *J Gerontol.* 1983;38:519-524.
6. Hattori N, Kurahachi H, Ikekubo K, et al. Effects of sex and age on serum GH binding protein levels in normal adults. *Clin Endocrinol.* 1991;35:295-297.
7. Zadik Z, Chalew SA, McCarter RJ, Meistas M, Kowarski AA. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. *J Clin Endocrinol Metab.* 1985;60:513-516.
8. Lucey JV, Keane LV, O'Flynn K, Clare AW, Dinan TG. Gender and age differences in the growth hormone response to pyridostigmine. *Int Clin Psychopharmacol.* 1991;6:105-109.
9. Florini JR, Prinz PN, Vitiello MV, Hintz RL. Somatomedin-C levels in healthy young and old men: relationship to peak and 24-hour integrated levels of growth hormone. *J Gerontol.* 1985;40:2-7.
10. Yamamoto H, Sohmiya M, Oka N, Kato Y. Effects of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults. *Acta Endocrinol (Copenh).* 1991;124:497-500.
11. Rudman D, Feller AG, Nagrajit S, et al. Effects of human growth hormone in men over 60 years old. *N Engl J Med.* 1990;323:1-6.
12. Takahashi GS, Meites J. GH binding to liver in young and old female rats: relation to somatomedin-C secretion. *Proc Soc Exp Biol Med.* 1987;186:229-233.
13. Johanson AJ, Blizard RM. Low somatomedin-C levels in older men rise in response to growth hormone administration. *Johns Hopkins Med J.* 1981;149:115-117.
14. Rudman D, Feller AG, Cohn L, Shetty KR, Rudman IW, Draper MW. Effects of human growth hormone on body composition in elderly men. *Horm Res.* 1991;36(suppl):73-81.
15. Sonntag WE, Hylka VW, Meites J. Growth hormone restores protein synthesis in skeletal muscle of old male rats. *J Gerontol.* 1984;40:689-694.
16. Vitiello MV. Sleep disorders and aging: understanding the causes. *J Gerontol A Biol Sci Med Sci*. 1997;52:M189-M191.
17. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among older persons: an epidemiological study of three communities. *Sleep.* 1995;18:425-432.
18. Foley DJ, Monjan A, Simonsick EM, et al. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6800 persons over 3 years. *Sleep.* 1999;22(suppl 2):S366-S372.
19. National Institutes of Health Consensus Development Conference Statement. The treatment of sleep disorders of older people. *Sleep.* 1991;14:169-77.
20. Vitiello MV, Prinz PN, Williams DE, et al. Sleep disturbances in patients with mild-stage Alzheimer's disease. *J Gerontol.* 1990;45:M131-M138.
21. Vitiello MV, Larsen LH, Moe KE, et al. Objective sleep quality of healthy older men and women is differentially disrupted by nighttime periodic blood sampling via indwelling catheter. *Sleep.* 1996;19:304-311.
22. Partinen M, Hublin C. Epidemiology of sleep disorders. In: Kryger M, Roth T, Dement WC, eds. *Principles and Practice of Sleep Medicine.* 3rd ed. Philadelphia, Pa: WB Saunders; 2000:558-579.
23. Weyerer S, Dilling H. Prevalence and treatment of insomnia in the community. Results from the Upper Bavarian Field Study. *Sleep.* 1991;14:392-398.
24. Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. *J Clin Psychiatry.* 1992;53:34-39.
25. Hohagen F, Rink K, Kappler C, et al. Prevalence and treatment of insomnia in general practice: a longitudinal study. *Eur Arch Psychiatry Clin Neurosci.* 1993;242:329-336.
26. Angst J, Vollrath M, Koch R, Dobler-Mikola A. The Zurich Study. VII. Insomnia: symptoms, classification and prevalence. *Eur Arch Psychiatry Neurol Sci.* 1989;238:285-293.
27. Ohayon MM, Caulet M, Lemoine P. Comorbidity of mental and insomnia disorders in the general population. *Compr Psychiatry.* 1998;39:185-197.

28. Weissman MM, Grenwald S, Nino-Murcia G, et al. The morbidity of insomnia uncomplicated by psychiatric disorders. *Gen Hosp Psychiatry.* 1997;19:245-250.
29. Henderson S, Jorm AF, Scott LR, et al. Insomnia in the elderly: its prevalence and correlates in the general population. *Med J Aust.* 1995;162:22-44.
30. Ohayon MM, Caulet M, Philip P, et al. How sleep and mental disorders are related to complaints of daytime sleepiness. *Arch Intern Med.* 1997;157:2645-2652.
31. Roberts RE, Shema SJ, Kaplan GA. Prospective data on sleep complaints and associated risk factors in an older cohort. *Psychosom Med.* 1999;61:188-196.
32. Weissman MM, Grenwald S, Nino-Murcia G, et al. The morbidity of insomnia uncomplicated by psychiatric disorders. *Gen Hosp Psychiatry.* 1997;19:245-250.
33. Gislason T, Reynisdottir H, Kristbjarson H, et al. Sleep habits and sleep disturbances among the elderly—an epidemiological survey. *J Intern Med.* 1993;234:31-39.
34. Klink ME, Quan SF, Kaltenborn T, et al. Risk factors associated with complaints of insomnia in a general adult population: influence of previous complaints of insomnia. *Arch Intern Med.* 1992;152:1634-1637.
35. Pollack CP, Perlick D, Linsner JP, et al. Sleep problems in the community elderly as predictors of death and nursing home placement. *J Community Health.* 1990;15:123-135.
36. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. *JAMA.* 1982;248:333-335.
37. Ganguli M, Reynolds CF, Gilby JE. Prevalence and persistence of sleep complaints in a rural older community sample: the MoVIES project. *J Am Geriatr Soc.* 1996;44:778-784.
38. Hays JC, Blazer DG, Foley DJ. Risk of napping: excessive daytime sleepiness and mortality in an older community population. *J Am Geriatr Soc.* 1996;44:693-698.
39. Kojima M, Wakai K, Kawamora T, et al. Sleep patterns and total mortality: a 12-year follow-up study in Japan. *J Epidemiol.* 2000;10:87-93.
40. Newman AB, Spiekerman CF, Enright P, et al. Daytime sleepiness predicts mortality and cardiovascular disease in older adults. The Cardiovascular Health Study Research Group. *J Am Geriatr Soc.* 2000;48:115-123.
41. Wingard DL, Berkman LF. Mortality risk associated with sleeping patterns among adults. *Sleep.* 1983;6:102-107.
42. Kripke DF, Simons RN, Garfinkel L, et al. Short and long sleep and sleeping pills: is increased mortality associates? *Arch Gen Psychiatry.* 1979;36:103-116.
43. Bliwise DL. Sleep in normal aging and dementia. *Sleep.* 1993;16:40-81.
44. Institute of Medicine. *Report of a Study: Sleeping Pills, Insomnia, and Medical Practice.* Washington, DC: National Academy of Science; 1979.
45. Carskadon MA, Seidel WF, Greenblatt DJ, Dement WC. Daytime carryover of triazolam and flurazepam in elderly insomniacs. *Sleep.* 1982;5:361-371.
46. Roehrs TA, Roth T. Drugs, sleep disorders and aging. *Clin Ger Med.* 1989;5:395-404.
47. Åström C, Trojaborg W. Effect of growth hormone on human sleep EEG energy. *Clin Endocrinol.* 1992;36:241-245.
48. Åström C, Lindholm J. Growth hormone-deficient young adults have decreased deep sleep. *Neuroendocrinology.* 1990;51:82-84.
49. Drucker-Colin RR, Spanis CW, Hunyadi J, Sassin JF, McGaugh JL. Growth hormone effects on sleep and wakefulness in the rat. *Neuroendocrinology.* 1975;18:1-8.
50. Obal F Jr, Alfoldi P, Cady AB, Johannsen L, Sary G, Kreuger JM. Growth hormone–releasing factor enhances sleep in rats and rabbits. *Am J Physiol.* 1988;255(2 Pt 2):R310-R316.
51. Obal F Jr, Floyd R, Kapas L, Bodosi B, Krueger JM. Effects of systemic GHRH on sleep in intact and hypophysectomized rats. *Am J Physiol.* 1996;270(2 Pt 1):E230-E237.
52. Obal F Jr, Payne L, Kapas L, Opp M, Kreuger JM. Inhibition of growth hormone–releasing factor suppresses both sleep and growth hormone secretion in the rat. *Brain Res.* 1991;557:149-153.
53. Krueger JM, Obal F Jr, Fang J. Humoral regulation of physiological sleep: cytokines and GHRH. *J Sleep Res.* 1999;8(suppl 1):53-59.
54. Steiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F. Effects of growth hormone–releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. *Neuroendocrinology.* 1992;56:566-573.

Free paper

55. Shier T, Guldner J, Colla M, Holsboer F, Steiger A. Changes in sleep-endocrine activity after growh hormone–releasing hormone depend on time of administration. *J Neuroendocrinol.* 1997;9:201-205.

56. Kerkhofs M, Van Cauter E, Van Onderbergen A, Caufriez A, Thorner MO, Copinschi G. Sleep-promoting effects of growth hormone–releasing hormone in normal men. *Am J Physiol.* 1993;264:E594-E598.

57. Marshall L, Molle M, Boschen G, Stieger A, Fehm HL, Born J. Greater efficacy of episodic than continuous growth hormone–releasing hormone (GHRH) administration in promoting slow-wave sleep (SWS). *J Clin Endocrinol Metab.* 1996;81:1009-1013.

58. Marshall L, Boes N, Strasburger C, Born J, Fehm, HL. Differential influences in sleep of growth hormone-releasing hormone at different concentrations. *Exp Clin Endo Diabetes.* 1997;(suppl 1):113.

59. Garry P, Roussel B, Cohen R, et al. Diurnal administration of human growth hormone-releasing factor does not modify sleep and sleep-related growth hormone secretion in normal young men. *Acta Endocrinol (Copenh).* 1985;110:158-163.

60. Kupfer DJ, Jarrett DB, Ehlers CL. The effect of GRF on the EEG sleep of normal males. *Sleep.* 1991;14:87-88.

61. Murck H, Frieboes RM, Schier T, Steiger A. Longtime administration of growth hormone–releasing hormone (GHRH) does not restore the reduced efficiency of GHRH on sleep endocrine activity in 2 old aged subjects—a preliminary study. *Pharmacopsychiatry.* 1997;30:122-124.

62. Guldner J, Schier T, Friess E, Colla M, Holsboer F, Stieger A. Reduced efficacy of growth hormone-releasing hormone in modulating sleep endocrine activity in the elderly. *Neurobiol Aging.* 1997;18:491-495.

63. Cattell RB. *Abilities, their Structure, Growth and Action.* Boston, Mass: Houghton Mifflin; 1972.

64. Salthouse TA. The processing-speed theory of adult age differences in cognition. *Psychol Rev.* 1996;103:403-428.

65. Birren JE, Fisher LM. Aging and speed of behavior: possible consequences for psychological functioning. *Ann Rev Psychol.* 1995;46:329-353.

66. van Dam PS, Aleman A, de Vries WR, et al. Growth hormone, insulin-like growth factor I and cognitive function in adults. *Growth Horm IGF Res.* 2000;(suppl B):S69-S73.

67. Rollero A, Murialdo G, Fondi S, et al. Relationship between cognitive function, growth hormone and insulin-like growth factor I plasma levels in aged subjects. *Neuropsychobiology.* 1998;23:45-55.

68. Aleman A, Verhaar HJ, de Haan EHF, et al. Insulin-like growth factor-I and cognitive function in healthy older men. *J Clin Endocrinol Metab.* 1999;84:471-475.

69. Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. *Brain Res Rev.* 1998;27:1-39.

70. Connor B, Beilharz EJ, Williams C, et al. Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus. *Mol Brain Res.* 1997;49:283-290.

71. Johansson JO, Larson G, Andersson M, et al. Treatment of growth hormone–deficient adults with recombinant human growth hormone increases in concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. *Neuroendocrinology.* 1995;61:57-66.

72. Nyberg F, Burman P. Growth hormone and its receptors in the central nervous system: location and functional significance. *Horm Res.* 1996;45:18-22.

73. Adem A, Jossan SS, d'Argy R, et al. Insulin-like growth factor 1 (IGF-1) receptors in the human brain: quantitative autoradiographic localization. *Brain Res.* 1989;503:299-303.

74. Nyberg F. Aging effects on growth hormone receptor binding in the brain. *Exp Gerontol.* 1997;32:521-528.

75. Lai Z, Roos P, Zhai O, et al. Age-related reduction of human growth hormone-binding sites in the human brain. *Brain Res.* 1993;621:260-266.

76. Aleman A, Verhaar HJ, DeHaan EH, et al. Insulin-like growth factor-I and cognitive function in healthy older men. *J Clin Endocrinol Metab.* 1999;84:471-475.

77. Vitiello MV, Merriam GR, Moe KE, et al. IGF-I correlates with cognitive function in healthy older men and estrogenized women. *Gerontologist.* 1999;39(suppl 1):6.

78. Sartorio A, Conti A, Molinari E, Riva G, Morabito F, Faglia G. Growth, growth hormone, and cognitive functions. *Horm Res.* 1996;45:23-29.

79. Deijen JB, de Boer H, Blok GJ, van der Veen EA. Cognitive impairments and mood disturbances in growth hormone deficient men. *Psychoneuroendocrinology.* 1996;21:313-322.

80. Soares Cd, Musolino NR, Cunha Neto M, et al. Impact of recombinant human growth hormone (RH-GH) treatment on psychiatric, neuropsychological and clinical profiles of GH deficient adults. A placebo-controlled trial. *Arq Neuropsiquiatr.* 1999;57:182-189.

81. Deijen JB, de Boer H, van der Veen EA. Cognitive changes during growth hormone replacement in adult men. *Psychoneuroendocrinology.* 1998;23:45-55.

82. Baum HB, Katznelson L, Sherman JC, et al. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. *J Clin Endocrinol Metab.* 1998;83:3184-3189.

83. Merriam GR, Barsness S, Drolet G, et al. Responses to a GH-releasing hormone in normal aging: effects of gender and estrogen replacement. Presented at: the Endocrine Society Annual Meeting; June 21-24, 2000; Toronto, Ontario. Abstract 1634.

84. Cook DM, Ludlum WH. Route of estrogen helps to determine growth hormone (GH) replacement dose in GH-deficient adults. *J Clin Endocrinol Metab.* 1999;84:3956-3960.

85. Schwartz RS, Buchner D, Merriam G, et al. Exercise and GHRH(1-29) treatment of the elderly. Presented at: the Endocrine Society Annual Meeting; June 21-24, 2000; Toronto, Ontario. Abstract 218.

86. Schwartz R, Merriam G, Vitiello M, Barsness S, Hastings R, Buchner D. GHRH and Exercise effects on body composition in healthy older women. *J Am Geriatr Soc.* 2000;48:S115.

87. Cress ME, Buchner DM, Questad KA, Esselman PC, deLateur BJ, Schwartz RS. Continuous-scale physical functional performance in healthy older adults: a validation study. *Arch Phys Med Rehabil.* 1996;77:1243-1250.

88. Schwartz R, Merriam G, Cress M, et al. GHRH and exercise effects on strength and function. *J Am Geriatr Soc.* 2000;48:S116.

89. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res.* 1989;28:193-213.

90. Vitiello MV, Mazzoni G, Moe KE; et al. GHRH treatment may improve cognitive function in the healthy elderly. *Gerontologist.* 2000;40(suppl 1):39.

91. Cummings DE, Merriam GR. Age-related changes in growth hormone secretion: should the somatopause be treated? *Semin Reprod Endocrinol.* 1999;14:311-325.

92. Swierstra BA, van der Lely AJ, Jauch KW, Attanasio AF. Human growth hormone in elderly patients with accidental hip fracture. Presented at: the American Academy of Orthopedic Surgeons Annual Meeting; March 15-19, 2000; Orlando, Fla. Abstract 011.